Return to homepagePandemic Pact

Characterization of modulators of the angiotensin-renin system with regard to their effect on an infection with SARS-CoV-2 (CARS)

  • Funded by Federal Ministry of Research, Technology and Space (BMFTR)
  • Total publications:0 publications

Grant number: 01KI20179

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2020
    2020

  • Known Financial Commitments (USD)

    $58,500.01

  • Funder

    Federal Ministry of Research, Technology and Space (BMFTR)

  • Principal Investigator

    Dr. Susanne Schiffmann

  • Research Location

    Germany

  • Lead Research Institution

    Fraunhofer-Gesellschaft, München

  • Research Priority Alignment

    N/A

  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Pathogen morphology, shedding & natural history

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

It is currently being discussed whether clinically used active ingredients such as modulators of the angiotensin-renin system could accelerate an infection with SARS-CoV-2. In order to clarify this question, a time-resolved virus infection assay will be established. The assay will help in identifying active substances that promote virus replication, in particular the effect of modulators of the angiotensin renin system on SARS-CoV-2 cell cytotoxicity. In addition, it was postulated that the ACE2 expression downregulated by SARS-CoV-2 is at least partially responsible for the permeability of the lung epithelium induced by SARS-CoV-2 and related lung injury. Therefore it should be tested whether modulators of the angiotensin-renin system affect the permeability of the epithelial tissue. Our findings can fundamentally contribute to the treatment of patients who use modulators of the angiotensin-renin-systems.